“showed a trend”

In men the LA-LV deviation angle showed a trend for greater angle (end-diastolic (ED) angle 26.9 ± 6.2° in women and 29.8 ± 5.9° in men, p = 0.07 and end-systolic (ES) angle 19.5 ± 5.9 and 22.6 ± 6.4, p = 0.06, respectively).

The results showed a trend of reduction in the BMI z-score in the AVG group, whereas the BMI z-score among the control group was essentially unchanged ( P =.07).

Although not statistically significant, BPH showed a trend as a risk factor for relapse (OR, 2.9; 95% CI, 0.9 to 9.5; P = 0.07).

Based on Faith Phylogenetic diversity that assessed using the Tukey Honest Significant Difference method, the probable pigs had a higher phylogenetic diversity level compared to healthy pigs ( p = 0.045) and showed a trend towards greater diversity than the confirmed group ( p = 0.07) (Fig. 1 b).

These patients showed a trend towards more vessel inflammation in the muscle biopsy (10% vs 1%, P = 0.07), less myalgia (33% vs 54%, P = 0.07), lower CK median levels (459 vs 823, P = 0.06) and lower cellularity in the biopsy characterized by less CD68 + (68% vs 85%, P = 0.07) and CD45 + cells (64% vs 79%, P = 0.10) when compared with the anti-FHL1 – counterpart ( Supplementary Table S3 , available at Rheumatology online).

In patients with non-Class I mutations, tobacco users treated with ICI-based therapies (n=36) showed a trend towards improved PFS (14.2 vs. 7.5 months; p = 0.07) and OS (18.8 vs. 9.7 months; p = 0.07) compared to never-smokers (n=6).

The composite biomarker was prognostic for progression in the 177 Lu + SBRT group (time ratio [TR], 1.8 [95% CI, 1.21 to 2.66]; P = .0037; Fig 3 C) and showed a trend in the SBRT group (TR, 1.6 [95% CI, 0.96 to 2.66]; P = .07; Fig 3 D).

The secondary analyses showed a trend toward significant stimulation effect for stride length of single-task walking (F = 3.422, p = 0.070, η 2 p = 0.063) and dual-task walking (F = 2.914, p = 0.094, η 2 p = 0.054).

We found a trend towards an increase in the TNFR1 + classical monocyte cell population [Ctl: 1.87% (1.21–2.52) and IS: 2.54% (2.07–4.27), U = 51.5, p = 0.07] in ischemic stroke patients compared to controls, whereas the TNFR1 + intermediate cell population showed a trend towards a decrease [Ctl: 1.35% (0.44–2.52) and IS: 0.49% (0.13–1.04), U = 52, p = 0.07] ( Figure 3 f).

S1-specific IgG showed a trend toward a correlation with IgA ( r = 0.423, p = 0.07; Figure 5D ), while RBD-specific IgG correlated significantly with IgA ( r = 0.635, p < 0.003; data not shown).

There was no significant decay of anti-S trimer IgG over time (delta per month: −0.02, p = 0.5); however, anti-RBD antibody showed a trend toward slight decay over time (delta per month: −0.04, p = 0.07), and anti-NP significantly decayed over time (delta per month: −0.15, p < 0.001).

Post hoc analysis showed a trend towards a lower salivary NO 2 − , but not salivary NO 3 −, concentration, in samples received after 3 or more days compared with 2 or 1 days ( p = 0.07 and p = 0.08, respectively). 3.6.

Daughters with PCOS also showed a trend to lower methylation levels of TET1 as compared with controls (p = 0.07; Figure 7 C).

The HF steers fed LCP-LME during Phase 1 showed a trend for greater LWG than HF steers fed HCP-LME during Phase 2 ( P = 0.07).

Serum uric acid decreased significantly (p = 0.012), while haemoglobin showed a trend towards improvement (p = 0.070).

In patients with MRD <0.1% at the end of Induction-1, HCT showed a trend of improved 3-year DFS of 90.7±6.5% versus 74.1±5.8% for chemotherapy ( P =0.07).

The T:M ratio in WT αS did not reveal a significant change, but the tetramer level (αS60) showed a trend of rising ( p = 0.07).

Addition of IFNγ and IFNβ together also showed a trend towards compromised CREB phosphorylation (p = 0.07) ( Fig 4e ), suggesting that these interferons are candidates for CREB-mediated reduction of gluconeogenic gene expression in the liver during pulmonary TB.

Patients with hypertension in our series showed a trend towards a more frequent readmission (p=0.07).

Western blotting showed a band corresponding to the predicted 43‐kDa molecular weight for asporin in rToF‐PVR samples and showed a trend toward increased expression ( P =0.07) compared with RV donor samples.

Moreover, the presence of >30% TIL was seen only in patients who experienced a clinical benefit (25% vs 0%, p=0.22) and the tumors of patients who experienced a clinical benefit from therapy showed a trend towards greater TIL compared with those who lacked clinical benefit (27% vs 11%, p=0.07), suggesting TIL levels may serve as both a prognostic and possibly predictive biomarker, requiring further validation ( online supplemental figure 2 ).

We note that the pain intensity model showed a trend for a group-by-frequency of use interaction ( p = .07), suggesting that at average and higher frequencies of use, the CBD group had the lowest levels of pain intensity (see Supplementary Table S2 ).

Multivariable analysis ( Supplementary Table , online only) showed a trend toward more MAEs in the PMSG group without reaching statistical significance (odds ratio, 3.76; 95% confidence interval, 0.92-15.41; P = .07).

Presence of a DNMT3A mutation was significantly associated with achievement of CR ( P = 0.045); accordingly, patients with co-mutations in genes in the DNA methylation functional category showed a trend toward attainment of CR ( P = 0.07) ( Fig. 2 ).

Intervention had no effect on time to first exacerbation (HR 0.65, 95% CI 0.21 to 2.07, P = .24), but showed a trend toward a 39% decreased frequency of exacerbations (RR = 0.61, 95% CI 0.35 to 1.03, P = .070) for the adjusted models, respectively.